TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38762282

Group type: EXPERIMENTAL
Intervention: SDDR-PEP provided to household contacts of patients with leprosy (Arm 2)
Number of subjects: 109436

Group type: EXPERIMENTAL
Intervention: SDDR-PEP extended to anyone living within 100 m (Arm 3)
Number of subjects: 109436

Group type: EXPERIMENTAL
Intervention: SDDR-PEP offered to household contacts and anyone living within 100 m testing positive to anti-phenolic glycolipid-I (Arm 4)
Number of subjects: 109436

Group type: EXPERIMENTAL
Intervention: Individual level SDDR-PEP
Number of subjects: 109436

Group type: COMPARATOR
Intervention: Comparator arm (no PEP provided)
Number of subjects: 109436
Study: 38762348

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks plus 5-fluorouracil, leucovorin, oxaliplatin (cohort B)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks plus 5-fluorouracil, leucovorin, irinotecan (cohort D)
Number of subjects: 63
Study: 38762353

Group type: EXPERIMENTAL
Intervention: FTD/TPI + oxaliplatin + nivolumab
Number of subjects: 118

Group type: COMPARATOR
Intervention: FOLFOX + nivolumab
Number of subjects: 118
Study: 38762360

Group type: EXPERIMENTAL
Intervention: Recombinant protein (SCB-2019, Clover)
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Adenovirus-vector (ChAdOx1-S, AstraZeneca/Fiocruz)
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: mRNA (BNT162b2, Pfizer/Wyeth)
Number of subjects: 772

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 772
Study: 38762396

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fascia iliaca block with ropivacaine 0.5%
Number of subjects: 134

Group type: COMPARATOR
Intervention: Sham block with saline
Number of subjects: 134
Study: 38762425

Group type: EXPERIMENTAL
Intervention: Psychosexual development theory-based breastfeeding education
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard discharge education
Number of subjects: 40
Study: 38762482

Group type: EXPERIMENTAL
Intervention: LISTERINE® Cool Mint Antiseptic (LCM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol-containing prototype mouthrinse (ACPM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroalcohol control rinse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol-free prototype mouthrinse (AFPM)
Number of subjects: 0
Study: 38762486

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) for 8 weeks
Number of subjects: 300

Group type: COMPARATOR
Intervention: Mediterranean diet for 8 weeks
Number of subjects: 300
Study: 38762522

Group type: EXPERIMENTAL
Intervention: Bivalent BA.1 and BA.5 vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S primed participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mRNA-primed and bivalent BA.5 boosted participants
Number of subjects: 0
Study: 38762578

Group type: EXPERIMENTAL
Intervention: AKI (Acute Kidney Injury) without CKRT (Continuous Kidney Replacement Therapy)
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: AKI (Acute Kidney Injury) with CKRT (Continuous Kidney Replacement Therapy)
Number of subjects: 759

Group type: COMPARATOR
Intervention: No AKI
Number of subjects: 759
Study: 38762708

Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invasive ventilation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-invasive respiratory support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creatinine level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: History of coronary disease
Number of subjects: 0
Study: 38762719

Group type: COMPARATOR
Intervention: Postprandial total GDF15 levels in MASLD patients
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: C-peptide levels in people with obesity
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: GIP levels in lean individuals
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fasting total GDF15 levels
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Postprandial GDF15 levels
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Incremental area under the curve of total and H-specific GDF15
Number of subjects: 42
Study: 38762720

Group type: EXPERIMENTAL
Intervention: Combination treatment (duloxetine + web-based self-guided CBT) with phone-based motivational interviewing (MI)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Combination treatment (duloxetine + web-based self-guided CBT) without phone-based MI
Number of subjects: 280

Group type: COMPARATOR
Intervention: Duloxetine monotherapy
Number of subjects: 280
Study: 38762727

Group type: EXPERIMENTAL
Intervention: i-MaCHeL programme (web-based intervention)
Number of subjects: 46
Study: 38762729

Group type: EXPERIMENTAL
Intervention: Deep extubation (group D)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Awake extubation (group A)
Number of subjects: 202
Study: 38762734

Group type: EXPERIMENTAL
Intervention: BMC treatment (autologous bone marrow concentrate and platelet products)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 51
Study: 38762797

Group type: EXPERIMENTAL
Intervention: Pamrevlumab (30 mg/kg administered intravenously every 3 weeks; n=181)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo (n=175)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study: 38762798

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1 g intravenously every 6 hours for 5 days)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 447
Study: 38763104

Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg orally twice daily plus nivolumab 3 mg/kg intravenously every 2 weeks (high-MET group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg orally twice daily plus nivolumab 3 mg/kg intravenously every 2 weeks (low-MET group)
Number of subjects: 46
Study: 38763165

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38763153

Group type: COMPARATOR
Intervention: Short-course ADT (6 months)
Number of subjects: 1523

Group type: EXPERIMENTAL
Intervention: Long-course ADT (24 months)
Number of subjects: 1523
Study: 38763154

Group type: EXPERIMENTAL
Intervention: Short-course ADT (6 months) with postoperative radiotherapy
Number of subjects: 1480

Group type: COMPARATOR
Intervention: No ADT with postoperative radiotherapy
Number of subjects: 1480
Study: 38763257

Group type: EXPERIMENTAL
Intervention: COMT minor allele carriers (T, A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: COMT major allele carriers (C, G)
Number of subjects: 0
Study: 38763303

Group type: EXPERIMENTAL
Intervention: RLRL therapy combined with orthokeratology (RCO)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Orthokeratology
Number of subjects: 48
Study: 38763306

Group type: EXPERIMENTAL
Intervention: Multilevel intervention targeting system, providers, and parents
Number of subjects: 8
Study: 38763307

Group type: EXPERIMENTAL
Intervention: Lumen-coached PST
Number of subjects: 200

Group type: COMPARATOR
Intervention: Human-coached PST
Number of subjects: 200

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 200
Study: 38763491

Group type: EXPERIMENTAL
Intervention: Local resection (LR)
Number of subjects: 0
Study: 38763619

Group type: EXPERIMENTAL
Intervention: Nerve-stimulated isometric torques of the ankle dorsiflexors
Number of subjects: 5

Group type: COMPARATOR
Intervention: Manual Muscle Tests (MMT)
Number of subjects: 5
Study: 38763960

Group type: EXPERIMENTAL
Intervention: PROSPERO collaborative information system
Number of subjects: 27
Study: 38764430

Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine (500 mg/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38764445

Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 67
Study: 38764606

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg (PRN)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg (EOD+PRN)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg (overall treatment)
Number of subjects: 1800
Study: 38764682

Group type: EXPERIMENTAL
Intervention: JAB-2485, a small-molecule inhibitor of AURKA
Number of subjects: 0
Study: 38765190

Group type: EXPERIMENTAL
Intervention: BASDAI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASDAS
Number of subjects: 0
Study: 38765202

Group type: EXPERIMENTAL
Intervention: 75.0 Gy in 30 fractions with concurrent bevacizumab (BEV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard plans (not specified dosage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental plans (75.0 Gy in 30 fractions)
Number of subjects: 0
Study: 38765524

Group type: EXPERIMENTAL
Intervention: CRADI-8 positive for colorectal symptoms
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Anal incontinence
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: PFDI-20
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: POPDI
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: UDI6
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: P-QoL social limitation
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: P-QoL sleep-energy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: P-QoL severity
Number of subjects: 113
Study: 38765567

Group type: EXPERIMENTAL
Intervention: Sparsentan 800 mg once daily
Number of subjects: 371

Group type: COMPARATOR
Intervention: Irbesartan 300 mg once daily
Number of subjects: 371
Study: 38765784

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (previously received)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acupuncture-naïve participants
Number of subjects: 0
Study: 38766034

Group type: EXPERIMENTAL
Intervention: Enhanced patient-reported outcomes (PROs) including LURN Symptom Index (SI)-29 and AUA-SI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine clinical tests integrated with PRO assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychometric properties of the LURN SIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Care-coordination recommendations based on PROs
Number of subjects: 0
Study: 38766125

Group type: EXPERIMENTAL
Intervention: Xanthine oxidase inhibitors (XOIs) for urate-lowering treatment (ULT)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Xanthine oxidase inhibitors (XOIs)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Febuxostat (a type of xanthine oxidase inhibitor)
Number of subjects: 49
Study: 38766126

Group type: EXPERIMENTAL
Intervention: eIF4A inhibitor zotatifin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with eIF4A inhibitor zotatifin and fulvestrant
Number of subjects: 0
Study: 38766254

Group type: EXPERIMENTAL
Intervention: Food Literacy and Nutrition (FLAN) curriculum
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nutrition information-only control
Number of subjects: 39
Study: 38766513

Group type: EXPERIMENTAL
Intervention: Culturally tailored weight loss intervention
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 169
Study: 38766567

Group type: EXPERIMENTAL
Intervention: Pamphlet-supported counseling about the benefits of family planning
Number of subjects: 347

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 347
Study: 38767159

Group type: EXPERIMENTAL
Intervention: Biomimetic collagen-hydroxyapatite scaffold (CHAS) augmented with filtered bone marrow aspirate (fBMA)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Biomimetic collagen-hydroxyapatite scaffold (CHAS)
Number of subjects: 78
Study: 38767193

Group type: EXPERIMENTAL
Intervention: Aquatic exercise for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aerobic exercise for 12 weeks
Number of subjects: 60
Study: 38767196

Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 779

Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 779
Study: 38767222

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF) utilizing a limited contact dynamic compression plate and screw construct
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonoperative treatment with closed reduction and below-elbow casting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 0
Study: 38767244

Group type: EXPERIMENTAL
Intervention: Leadless pacemaker in wireless communication with a subcutaneous ICD
Number of subjects: 293
Study: 38767248

Group type: EXPERIMENTAL
Intervention: Evaluation by a pulmonologist and an asthma-COPD educator who initiated guideline-based care
Number of subjects: 508

Group type: COMPARATOR
Intervention: Usual care by primary care practitioner
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Evaluation by a pulmonologist and an asthma-COPD educator
Number of subjects: 508
Study: 38767445

Group type: EXPERIMENTAL
Intervention: IN.PACT DCB (Medtronic) treatment
Number of subjects: 100
Study: 38767513

Group type: EXPERIMENTAL
Intervention: Neurocognitive training (NT) administered weekly for 10 consecutive weeks, supplemented by a structured home exercise programme for 6 days a week over the same 10-week period.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Neurocognitive training (NT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Typically developing (TD) children
Number of subjects: 14
Study: 38767614

Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg subcutaneous every 2 weeks)
Number of subjects: 935

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 935
Study: 38767650

Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab (nivo-ipi)
Number of subjects: 0
Study: 38767694

Group type: EXPERIMENTAL
Intervention: Intermittent phototherapy (IPT) - 2 cycles of 1 h on and 2 h off in a 6-h session
Number of subjects: 104

Group type: COMPARATOR
Intervention: Continuous phototherapy (CPT) - applied continuously for 6 h
Number of subjects: 104
Study: 38767780

Group type: EXPERIMENTAL
Intervention: RSV-induced hospitalisation
Number of subjects: 138
Study: 38767872

Group type: EXPERIMENTAL
Intervention: Restricted sleep (mean duration 4 hours, 12 minutes)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Total body fat percentage (TBF%) above 42
Number of subjects: 61
Study: 38767937

Group type: EXPERIMENTAL
Intervention: Esmethadone (REL-1017)
Number of subjects: 0
Study: 38767949

Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS) performed by general practitioners (GPs)
Number of subjects: 151
Study: 38767958

Group type: EXPERIMENTAL
Intervention: 5waysA intervention (web-based, 2 webinars, SMS reminders over 10 weeks)
Number of subjects: 969

Group type: COMPARATOR
Intervention: Waiting list control group (active or passive)
Number of subjects: 969
Study: 38767985

Group type: EXPERIMENTAL
Intervention: ACTIVE (5.5-h sitting with 2-min walking at 6.4 km·h -1 every 20 min)
Number of subjects: 26

Group type: COMPARATOR
Intervention: SIT (5.5-h uninterrupted sitting)
Number of subjects: 26
Study: 38768231

Group type: EXPERIMENTAL
Intervention: Gardasil-9 (3 doses administered intramuscularly at 0, 2, and 6 months)
Number of subjects: 0
Study: 38768283

Group type: COMPARATOR
Intervention: Total aortic arch repair
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Ascending aortic repair
Number of subjects: 1199
Study: 38768299

Group type: EXPERIMENTAL
Intervention: Conduction System Pacing (CSP)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Biventricular Pacing (BiVP)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: CSP
Number of subjects: 69

Group type: COMPARATOR
Intervention: BiVP
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: CSP and BiVP
Number of subjects: 69
Study: 38768428

Group type: EXPERIMENTAL
Intervention: HBI0101 (BCMA CART) therapy, 800 × 10^6 CART cells
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HBI0101 (BCMA CART) therapy
Number of subjects: 50
Study: 38768450

Group type: EXPERIMENTAL
Intervention: CADx-assisted histologic predictions
Number of subjects: 1252

Group type: COMPARATOR
Intervention: CADx-unassisted histologic predictions
Number of subjects: 1252
Study: 38768462

Group type: EXPERIMENTAL
Intervention: Digestive system invasion
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Genitourinary system invasion
Number of subjects: 172

Group type: COMPARATOR
Intervention: Gynecological system invasion
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Type of organs invaded by CRC
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Risk stratification based on age and type of organ invasion
Number of subjects: 172
Study: 38768468

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 330

Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 330
Study: 38768617

Group type: EXPERIMENTAL
Intervention: 4 months of BPaMZ (bedaquiline, pretomanid, moxifloxacin, pyrazinamide)
Number of subjects: 455

Group type: COMPARATOR
Intervention: 6 months of HRZE (isoniazid, rifampicin, pyrazinamide, ethambutol)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: 6 months of BPaMZ
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: 4 months of BPaMZ
Number of subjects: 455

Group type: COMPARATOR
Intervention: HRZE
Number of subjects: 455
Study: 38768626

Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase (0.25 mg/kg)
Number of subjects: 886

Group type: COMPARATOR
Intervention: Non-thrombolytic standard of care (control)
Number of subjects: 886
Study: 38768839

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RF CA)
Number of subjects: 2470
Study: 38768988

Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life inventory (PedsQL)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: 16D score
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Experience of care and transition readiness (quartile categorization)
Number of subjects: 512
Study: 38769049

Group type: EXPERIMENTAL
Intervention: Counselling and training on breastfeeding during antenatal visits, support by a trained female doctor, trained nurse at birth, and trained lady health worker at home for 6 months, supported by reading materials and videos via WhatsApp
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Counselling and training on breastfeeding
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard support provided within the hospital and at home
Number of subjects: 50
Study: 38769221

Group type: EXPERIMENTAL
Intervention: Pandemic-related media exposure
Number of subjects: 8337

Group type: EXPERIMENTAL
Intervention: Media consumption
Number of subjects: 8337
Study: 38769284

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 6-month (PP6M) injection
Number of subjects: 700

Group type: COMPARATOR
Intervention: Paliperidone palmitate 3-month (PP3M) injection
Number of subjects: 700
Study: 38769314

Group type: EXPERIMENTAL
Intervention: Hyperpure chlorine dioxide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash
Number of subjects: 60
Study: 38769330

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg q 12 hourly) plus Metronidazole (800 mg q 8 hourly) for 2 weeks
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cefixime (200 mg q 12 hourly) plus Metronidazole (800 mg q 8 hourly) for 2 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Cefixime
Number of subjects: 140
Study: 38769431

Group type: EXPERIMENTAL
Intervention: ARC (non-invasive spinal cord electrical stimulation)
Number of subjects: 0
Study: 38769543

Group type: EXPERIMENTAL
Intervention: Modified TIL therapy regimen (low-dose cyclophosphamide lymphodepletion followed by TIL infusion without intravenous IL-2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Modified TIL therapy regimen
Number of subjects: 14
Study: 38769552

Group type: EXPERIMENTAL
Intervention: Lower progesterone profile
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Upper progesterone profile
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Lower serum 17-hydroxyprogesterone profile
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Upper serum 17-hydroxyprogesterone profile
Number of subjects: 95
Study: 38769562

Group type: EXPERIMENTAL
Intervention: Prediabetes group (HbA1c 5.7-6.4%)
Number of subjects: 3910

Group type: COMPARATOR
Intervention: Normoglycemia group (HbA1c < 5.7%)
Number of subjects: 3910

Group type: EXPERIMENTAL
Intervention: Diabetes group (HbA1c ≥ 6.5%)
Number of subjects: 3910
Study: 38769624

Group type: EXPERIMENTAL
Intervention: Sleep hygiene measures and mindfulness meditation (relaxation audio) for 5 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no guidance for therapies)
Number of subjects: 36
Study: 38769643

Group type: EXPERIMENTAL
Intervention: 177 Lu-PSMA-617 RLT augmented by 1 or more cycles of 225 Ac-PSMA-617
Number of subjects: 33
Study: 38769923

Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD) management practices
Number of subjects: 3477

Group type: EXPERIMENTAL
Intervention: Demographic and clinical characteristics of COPD patients
Number of subjects: 3477
Study: 38769974

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine booster dose (third vaccine dose)
Number of subjects: 123
Study: 38770009

Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneously every 4 weeks for 52 weeks
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo subcutaneously every 4 weeks for 52 weeks
Number of subjects: 300
Study: 38770592

Group type: EXPERIMENTAL
Intervention: Deucravacitinib at 6 mg QD
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Deucravacitinib at 12 mg QD
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 38770686

Group type: EXPERIMENTAL
Intervention: Daily Cannabidiol Administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo or standard treatment not specified)
Number of subjects: 0
Study: 38770764

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0